Your browser doesn't support javascript.
loading
Fluoroquinolone resistance and clinical characteristics of acute bacterial prostatitis in Japan: A multicenter study by the Japanese research group for urinary tract infection.
Matsumoto, Masahiro; Hamasuna, Ryoichi; Wada, Koichiro; Sadahira, Takuya; Shigemura, Katsumi; Maeda, Kouki; Hiyama, Yoshiki; Togo, Yoshikazu; Nagasawa, Seiji; Yamanaka, Kazuaki; Shigehara, Kazuyoshi; Kobayashi, Kanao; Tsuchiya, Haruki; Miyazaki, Jun; Nakagawa, Tohru; Ishikawa, Kiyohito; Takahashi, Satoshi; Fujimoto, Naohiro; Yamamoto, Shingo.
Afiliação
  • Matsumoto M; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, The Japanese Research Group for Urinary Tract Infection (JRGU), Japan. Electronic address: mmatsumoto@med.uoeh-u.ac.jp.
  • Hamasuna R; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, The Japanese Research Group for Urinary Tract Infection (JRGU), Japan; Department of the Urology, Federation of National Public Service Personnel Mutual Aid Associations, Shin-Kokura Hospital, Kitakyushu, JRGU, J
  • Wada K; Department of Urology, Shimane University Faculty of Medicine, Shimane, JRGU, Japan.
  • Sadahira T; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JRGU, Japan.
  • Shigemura K; Department of Urology, Teikyo University School of Medicine, Tokyo, JRGU, Japan.
  • Maeda K; Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Hyogo, JRGU, Japan.
  • Hiyama Y; Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, JRGU, Japan.
  • Togo Y; Department of Urology, Kawanishi City Medical Center, Hyogo, JRGU, Japan.
  • Nagasawa S; Department of Urology, Kawanishi City Medical Center, Hyogo, JRGU, Japan.
  • Yamanaka K; Department of Urology, Shiga University of Medical Science, Shiga, JRGU, Japan.
  • Shigehara K; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa, JRGU, Japan.
  • Kobayashi K; Department of Urology, Chugoku Rosai Hospital, Hiroshima, JRGU, Japan.
  • Tsuchiya H; Department of Urology, Hitachi, Ltd. Hitachinaka General Hospital, Ibaraki, JRGU, Japan.
  • Miyazaki J; Department of Urology, International University of Health and Welfare Narita Hospital, Chiba, JRGU, Japan.
  • Nakagawa T; Department of Urology, Teikyo University School of Medicine, Tokyo, JRGU, Japan.
  • Ishikawa K; Department of Quality and Safety in Healthcare, Division of Infection Control and Prevention, Fujita Health University Hospital, Aichi, JRGU, Japan.
  • Takahashi S; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Hokkaido, JRGU, Japan.
  • Fujimoto N; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, The Japanese Research Group for Urinary Tract Infection (JRGU), Japan.
  • Yamamoto S; Department of Urology, Hyogo College of Medicine, Hyogo, JRGU, Japan.
J Infect Chemother ; 2024 Aug 14.
Article em En | MEDLINE | ID: mdl-39151550
ABSTRACT

OBJECTIVE:

This multicenter study aimed to analyze the risk factors for fluoroquinolone (FQ) resistance and to clarify the clinical characteristics of acute bacterial prostatitis (ABP) in Japan.

METHODS:

A total of 124 patients clinically diagnosed with ABP at 13 medical institutions participating in the Japanese Research Group for Urinary Tract Infection between January and December 2017 were retrospectively reviewed.

RESULTS:

Of the 124 patients included in this study, 37 were outpatients, and 87 were inpatients. The main underlying medical conditions before the onset of ABP were severe dysuria, urinary retention, transurethral manipulation, indwelling urinary catheter, and transrectal prostate biopsy (TRBx). The main symptoms were fever (≥37.5 °C), prostate tenderness, dysuria, micturition pain, urinary retention, and macrohematuria. Bacteremia was observed in 14 patients. Prostatic abscess was observed in three patients. Escherichia coli was the predominant organism, accounting for 48 % (51/106). FQ-resistant E. coli was detected in 33 % (17/51), and extended-spectrum beta-lactamase-producing E. coli in 12 % (6/51). TRBx (odds ratio [OR] = 48.60, 95 % confidence interval [CI] 5.49-430.00, p < 0.001) and inpatient status (OR = 29.00, 95 % CI 1.95-430.00, p = 0.014) were risk factors for the detection of FQ-resistant bacteria.

CONCLUSIONS:

The detection rate of FQ-resistant bacteria was significantly higher with TRBx ABP and inpatient status. These findings have important implications for the management of ABP and antimicrobial treatment, especially for TRBx ABP, which should be considered a separate category.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Infect Chemother Assunto da revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Infect Chemother Assunto da revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article